Health Care

Centene Corp. faces margin pressure and a negative P/E in a regulated Medicaid‑Medicare market, but growth could come from telehealth, AI claims and value‑based care.

Regeneron’s Dupixent gains EU approval for children 2‑11 with chronic spontaneous urticaria, expanding its portfolio, boosting investor appeal, and reflecting a trend toward pediatric biologics.

Sanofi’s latest regulatory wins—Japan orphan status for rilzabrutinib, EMA approval of Acoziborole, and EU recommendation for Dupixent CSU—show how a balanced portfolio of blockbuster, niche, and public‑health products can boost revenue and diversif…

Explore how Bristol‑Myers Squibb balances robust margins, value‑based reimbursement, and tech‑driven care to attract investors and boost patient access.

Corporate analysis of Straumann Holding AG: how Swiss dental‑device firm navigates regulatory risk, digital innovation, and subscription models to sustain growth and strong margins.

Fresenius shares dip slightly but stay above 52‑week highs, supported by strong dialysis demand, home‑care growth and a diversified portfolio that cushions against Eurozone inflation and tightening policy.

Merck KGaA’s market rise, value‑based contracts, and digital therapeutics drive stronger cash flow, higher margins and better patient outcomes in healthcare delivery.

Fisher & Paykel Healthcare’s latest broker consensus shows cautious optimism as the company’s shares hover near the 52‑week upper bound, reflecting strong fundamentals and growing demand in respiratory and neonatal care markets.

Explore Bristol‑Myers Squibb’s strong drug pipeline, solid safety record, and market resilience, and why investors view it as a stable biopharma pick.

Merck’s Phase III wins for Keytruda + WELIREG and Keytruda + Padcev could boost kidney‑cancer and bladder‑cancer sales by over $1 billion, reshaping the oncology landscape.